Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Oct 26;4(10):e855.
doi: 10.1371/journal.pntd.0000855.

Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study

Ahmed M Musa  1 , Brima Younis, Ahmed Fadlalla, Catherine Royce, Manica Balasegaram, Monique Wasunna, Asrat Hailu, Tansy Edwards, Raymond Omollo, Mahmoud Mudawi, Gilbert Kokwaro, Ahmed El-Hassan, Eltahir Khalil
Affiliations
Clinical Trial

Paromomycin for the treatment of visceral leishmaniasis in Sudan: a randomized, open-label, dose-finding study

Ahmed M Musa et al. PLoS Negl Trop Dis. .

Abstract

Background: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan. We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg/kg/day for 28 days) and at the higher dose of 20 mg/kg/day for 21 days.

Methods: This randomized, open-label, dose-finding, phase II study assessed the two above high-dose PM treatment regimens. Patients with clinical features and positive bone-marrow aspirates for VL were enrolled. All patients received their assigned courses of PM intramuscularly and adverse events were monitored. Parasite clearance in bone-marrow aspirates was tested by microscopy at end of treatment (EOT, primary efficacy endpoint), 3 months (in patients who were not clinically well) and 6 months after EOT (secondary efficacy endpoint). Pharmacokinetic data were obtained from a subset of patients weighing over 30 kg.

Findings: 42 patients (21 per group) aged between 4 and 60 years were enrolled. At EOT, 85% of patients (95% confidence interval [CI]: 63.7% to 97.0%) in the 20 mg/kg/day group and 90% of patients (95% CI: 69.6% to 98.8%) in the 15 mg/kg/day group had parasite clearance. Six months after treatment, efficacy was 80.0% (95% CI: 56.3% to 94.3%) and 81.0% (95% CI: 58.1% to 94.6%) in the 20 mg/kg/day and 15 mg/kg/day groups, respectively. There were no serious adverse events. Pharmacokinetic profiles suggested a difference between the two doses, although numbers of patients recruited were too few to make it significant (n = 3 and n = 6 in the 20 mg/kg/day and 15 mg/kg/day groups, respectively).

Conclusion: Data suggest that both high dose regimens were more efficacious than the standard 15 mg/kg/day PM for 21 days and could be further evaluated in phase III studies in East Africa.

Trial registration: ClinicalTrials.gov NCT00255567.

PubMed Disclaimer

Conflict of interest statement

CR was working for DNDi at the time of the study. MB is currently working at DNDi.

Figures

Figure 1
Figure 1. Flowchart of patients.
Figure 2
Figure 2. Semi-log plot of mean (SD) paromomycin (PM) concentrations (µg/mL) versus time (hours) after a single intramuscular injection.
Plasma PM concentrations on day 1 (D1), day 14 (D14), and day 26 (D26) for VL patients who received either 15 mg/kg (n = 6) or 20 mg/kg PM (n = 3).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Desjeux P. Leishmaniasis. Public health aspects and control. Clin Dermatol. 1996;14:417–423. - PubMed
    1. World Health Organization. Leishmaniasis. 2009. http://www.who.int/leishmaniasis/disease_epidemiology/en/index.html. Accessed 2009 Nov 26.
    1. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev. 2006;19:111–126. - PMC - PubMed
    1. Rijal S, Chappuis F, Singh R, Boelaert M, Loutan L, et al. Sodium stibogluconate cardiotoxicity and safety of generics. Trans R Soc Trop Med Hyg. 2003;97:597–598. - PubMed
    1. Thakur CP, Sinha GP, Pandey AK, Kumar N, Kumar P, et al. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases. Ann Trop Med Parasitol. 1998;92:561–569. - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources